Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 901 801 0?
Displaying drugs 526 - 550 of 1449 in total
AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Experimental
AZD-8165 is under investigation in clinical trial NCT01150812 (Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects).
Investigational
Experimental
BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).
Investigational
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
Investigational
Foslinanib is under investigation in clinical trial NCT03600233 (Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors).
Investigational
GW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).
Investigational
Investigational
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Investigational
Experimental
Withdrawn
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Investigational
Investigational
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Investigational
Experimental
Withdrawn
Investigational
Investigational
Displaying drugs 526 - 550 of 1449 in total